USP7 and lung neuroendocrine neoplasm: The identification of CCDC6 as a novel USP7 substrate has provided the rationale to establish that the USP7 inhibitor, P5091, by downregulating CCDC6 protein, can modulate the PARP-inhibitors sensitivity in lung neuroendocrine tumors [23].